Jakobsen Jarl A, Oyen Raymond, Thomsen Henrik S, Morcos Sameh K
Department of Radiology, Rikshospitalet University Hospital, Oslo, Norway.
Eur Radiol. 2005 May;15(5):941-5. doi: 10.1007/s00330-004-2601-0. Epub 2005 Jan 21.
The use of ultrasound contrast agents has increased over recent years. The Contrast Media Safety Committee (CMSC) of the European Society of Urogenital Radiology (ESUR) decided to review the safety of ultrasound contrast agents in humans and to draw up guidelines. A comprehensive literature search and review was carried out. The resulting report was discussed by the CMSC of ESUR and at the 11th European Symposium on Urogenital Radiology in Santiago de Compostela, Spain, in 2004. Ultrasound contrast agents approved for clinical use are well tolerated, and serious adverse reactions are rarely observed. Adverse events are usually minor (e.g. headache, nausea, altered taste, sensation of heat) and self-resolving. These symptoms may not be related to the ultrasound contrast materials as they have also been observed in placebo-control groups. Intolerance to some components may occur. Generalized allergy-like reactions occur rarely. Ultrasound contrast agents are generally safe. The ultrasound scanning time and the acoustic output should be kept to the lowest level consistent with obtaining diagnostic information. Adverse reactions should be treated symptomatically.
近年来,超声造影剂的使用有所增加。欧洲泌尿生殖放射学会(ESUR)的造影剂安全委员会(CMSC)决定审查超声造影剂在人体中的安全性并制定指南。进行了全面的文献检索和综述。ESUR的CMSC以及在2004年于西班牙圣地亚哥德孔波斯特拉举行的第11届欧洲泌尿生殖放射学研讨会上对所得报告进行了讨论。已批准用于临床的超声造影剂耐受性良好,很少观察到严重不良反应。不良事件通常较轻微(如头痛、恶心、味觉改变、热感)且可自行缓解。这些症状可能与超声造影剂无关,因为在安慰剂对照组中也观察到了这些症状。可能会出现对某些成分的不耐受。全身性过敏样反应很少发生。超声造影剂总体上是安全的。超声扫描时间和声输出应保持在与获取诊断信息相一致的最低水平。不良反应应进行对症治疗。